Andrew Tsai (Jefferies) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Andrew Tsai's stock ratings?

About 52% of Andrew's ratings were profitable over a one-year hold, with an average return of +8.8% per rating, measured by 13Foresight from historical prices.

Q: How is Andrew ranked?

Andrew Tsai is ranked #1386 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Andrew Tsai

JEF

Andrew Tsai

Jefferies

Wall Street Analyst

★★★☆☆

#1386

on 13Foresight · ranked by our own returns

52%

Success Rate

+8.9%

Average Return

14 of 27 calls profitable · -2.4% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 52% of Andrew Tsai's ratings turned a profit when each position was held for 1 year — averaging +8.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

48 Buy 16 Hold 0 Sell

Andrew's Stock Coverage 27 ratings · 2026-06-19

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
MRNA Moderna	Jun 16, 2026	HOLD	Hold +6.4% avg upside 38 analysts	$45.00 29.73% Downside	·
DFTX Definium Therapeutics	May 21, 2026	BUY	Strong Buy +44.9% avg upside 20 analysts	$35.00 42.98% Upside	+7.9%
ANRO Alto Neuroscience, Inc.	May 14, 2026	BUY	Strong Buy +33.3% avg upside 13 analysts	$35.00 53.83% Upside	-10.3%
CMPS COMPASS Pathways	May 14, 2026	BUY	Strong Buy +63.7% avg upside 18 analysts	$18.00 43.69% Upside	+12.4%
AXSM Axsome Therapeutics	May 01, 2026	BUY	Strong Buy -10.6% avg upside 28 analysts	$200.00 20.21% Downside	+22.0%
DRUG Bright Minds Biosciences	Apr 12, 2026	BUY	Strong Buy +120.9% avg upside 10 analysts	$145.00 139.02% Upside	-2.0%
BBIO BridgeBio Pharma	Mar 31, 2026	BUY	Strong Buy +38.3% avg upside 34 analysts	$100.00 50.94% Upside	-9.2%
PRAX Praxis Precision Medicines	Mar 31, 2026	BUY	Strong Buy +92.1% avg upside 24 analysts	$525.00 85.87% Upside	-16.2%
BIIB Biogen	Mar 12, 2026	BUY	Strong Buy +25.1% avg upside 51 analysts	$210.00 6.75% Upside	+7.4%
ATAI Atai Beckley N.V.	Mar 09, 2026	BUY	Strong Buy +230.1% avg upside 16 analysts	$10.00 146.22% Upside	+3.1%
XENE Xenon	Mar 09, 2026	BUY	Strong Buy +19.0% avg upside 28 analysts	$100.00 89.02% Upside	-16.5%
HELP Helus Pharma	Feb 01, 2026	BUY	Strong Buy +861.2% avg upside 12 analysts	$22.00 371.14% Upside	·
SRPT Sarepta Therapeutics	Jan 12, 2026	BUY	Buy +246.5% avg upside 49 analysts	$30.00 71.19% Upside	-25.5%
VNDA Vanda	Dec 31, 2025	HOLD	Strong Buy +253.1% avg upside 13 analysts	$7.50 29.30% Upside	-28.8%
VTGN VistaGen Therapeutics	Dec 17, 2025	HOLD	Hold +287.9% avg upside 8 analysts	$0.90 34.25% Upside	-30.2%
NERV Minerva Neurosciences	Dec 01, 2025	HOLD	Buy +68.3% avg upside 8 analysts	$5.00 11.91% Upside	+30.5%
STOK Stoke Therapeutics	Nov 24, 2025	BUY	Strong Buy +25.1% avg upside 18 analysts	$30.00 3.18% Downside	-1.1%
MPLT MapLight Therapeutics, Inc.	Nov 21, 2025	BUY	Strong Buy +32.5% avg upside 11 analysts	$32.00 11.12% Upside	+94.1%
ANNX Annexon Biosciences	Nov 11, 2025	BUY	Strong Buy +181.2% avg upside 13 analysts	$10.00 104.13% Upside	+72.4%
RCKT Rocket Pharmaceuticals	Aug 08, 2025	HOLD	Buy +395.9% avg upside 29 analysts	$3.00 10.54% Downside	+3.5%
LXRX Lexicon Pharmaceuticals	Aug 06, 2025	HOLD	Buy +98.6% avg upside 9 analysts	$0.85 57.74% Downside	+66.1%
SVRA Savara	Mar 26, 2025	BUY	Strong Buy +58.2% avg upside 17 analysts	$8.50 54.46% Upside	+94.4%
SUPN Supernus Pharmaceuticals	Mar 12, 2025	BUY	Strong Buy +22.1% avg upside 7 analysts	$40.00 9.92% Downside	+60.8%
RAPP Rapport Therapeutics, Inc.	Dec 07, 2024	BUY	Strong Buy +46.2% avg upside 12 analysts	$35.00 6.35% Downside	+43.7%
LONA LeonaBio	Sep 18, 2024	HOLD	Buy +13.9% avg upside 9 analysts	$0.50 93.94% Downside	-17.3%
RLMD Relmada Therapeutics	Sep 16, 2024	BUY	Buy +106.4% avg upside 15 analysts	$13.00 93.26% Upside	-47.2%
DYN Dyne Therapeutics	Jun 24, 2024	BUY	Strong Buy +93.5% avg upside 29 analysts	$42.00 112.07% Upside	-70.2%

🔒 22 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Andrew Tsai — Frequently Asked Questions

How accurate are Andrew Tsai's stock ratings?

Based on the calls 13Foresight could measure, about 52% of Andrew's ratings were profitable over a one-year hold, with an average return of +8.8% per rating, or -1.7% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Andrew ranked on 13Foresight?

Andrew Tsai is currently ranked #1386 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Andrew cover?

Andrew most recently has ratings on MRNA, DFTX, ANRO, CMPS, AXSM, DRUG, BBIO, PRAX, BIIB, ATAI, XENE, HELP and 15 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!